

1 This supplementary data file contains the following contents: Materials  
2 and methods, Supplementary Figures (S1~S3) and Supplementary Tables  
3 (S1~S5).

#### 4 **Materials and methods**

##### 5 **Animal experiments**

6 All animal works were proceeded according to the Guide for the  
7 Care and Use of Laboratory Animals. We used Vr:CD1 (ICR) mice as the  
8 embryo donor and recipient, which were purchased from Vital River  
9 Laboratories Company (Beijing, China). All mice were housed in specific  
10 pathogen free (SPF) grade cleanroom and maintained on a 12 hour dark/  
11 12 hour light cycle.

##### 12 **CRISPR/Cas9 plasmid**

13 CRISPR expression plasmid targeting Tbx3 locus was constructed as  
14 previously published study (Cong et al., 2013), the px330 plasmid was a  
15 gift from Dr. Zhang Feng (Broad Institute of MIT and Harvard),  
16 oligonucleotide for sgRNA were synthesized by Sangon Biotech  
17 Company (Shanghai, China).

18 The method for construction of CRISPR expression plasmid  
19 containing PGK-puro cassette, called px330-puro, was described as  
20 follow: first, using XhoI and XbaI to subclone the PGK-puro cassette into  
21 the Sall and XbaI sites of pCS2-TALEN-A-perr plasmid (a gift from Dr.  
22 Zhang Bo, Peking University) forming intermediate plasmid, which

23 called pCS2-puro. Second, digest and subclone sgRNA/Cas9 cassette of  
24 px330 into pCS2-puro by AflIII and NotI.

### 25 **Targeting vector**

26 To construct donor vector, we amplified chromosome sequence  
27 flanking the stop codon of Tbx3 locus as homology arms. When  
28 designing primers for amplifying 5'-homologous arm, we introduced  
29 degenerate bases to remove CRISPR targeting site within the donor  
30 vector. Through fusion PCR, eGFP was fused with 5'-homologous arm  
31 preceded by a 2A self-cleavage peptide.

### 32 **Mouse ES cell *in vitro* culture, differentiation, and electrotransfection**

33 G4 (129×C57BL/6) ES cells (from Nagy Lab) were grown and  
34 maintained in previously published methods with a little modification  
35 (George et al., 2007). We cultured ES cells in Dulbecco's Modified Eagle  
36 Medium (DMEM) with high glucose (Invitrogen), supplemented with 15%  
37 ES cell-grade FBS (Gibco), 2mM GlutaMAX, 1mM sodium pyruvate,  
38 2mM nonessential amino acids, 0.1mM 2-mercaptophenol, 1000units/ml  
39 Leukemia Inhibitory Factor (Millipore), 3μM CHIR99021 and 1μM  
40 PD0325901 (2i).

41 For differentiation, we use standard embryonic bodies (EB)  
42 formation method. ESCs were cultured in non-adherent conditions at a  
43 density of  $1 \times 10^5$  cells/ml for 2 days on a rotator with 40 rpm. The formed  
44 EBs were cultured on plated coated with gelatin for another 5 days before

45 detection lineage markers with immunofluorescence staining.

46 Electrotransfection was performed using Nucleofector Kits for  
47 Mouse Embryonic Stem Cells (Lonza) following manufacturer's protocol.  
48 To yield *Tbx3-2A-GFP* cells,  $2 \times 10^6$  cells were transfected with 3  $\mu$ g  
49 CRISPR/Cas9 expression plasmid and 1  $\mu$ g donor plasmid using A-030  
50 program. If need drug selection, 2  $\mu$ g/ml puromycin was added 24 hours  
51 post transfection and removed 3 days post transfection.

### 52 **T7 endonuclease I assay and indel rate analysis**

53 G4 cells were transfected with plasmid DNA as described above and  
54 harvested 2 days post transfection. Genomic DNA of  $2 \times 10^6$  cells were  
55 extracted using DNeasy Blood & Tissue Kit (Qiagen) following  
56 manufacturer's protocol.

57 Genomic region flanking targeting site was amplified using  
58 high-fidelity DNA polymerase (TransGen Biotech), and the product was  
59 purified with QIAquick PCR Purification Kit (Qiagen) following  
60 manufacturer's protocol. A total of 400ng of the purified PCR product  
61 was mixed with 2  $\mu$ l NEBuffer 2 (NEB) and ultrapure water was added to  
62 a final 20  $\mu$ l volume. Heteroduplex were formed using a Thermocycler in  
63 following program: 95  $^{\circ}$ C for 10min, 95  $^{\circ}$ C to 85  $^{\circ}$ C ramping at  $-2$   $^{\circ}$ C /s,  
64 85  $^{\circ}$ C for 1min, 85  $^{\circ}$ C to 75  $^{\circ}$ C ramping at  $-0.3$   $^{\circ}$ C /s, 75  $^{\circ}$ C for 1min, 75  $^{\circ}$ C to  
65 65  $^{\circ}$ C ramping at  $-0.3$   $^{\circ}$ C /s, 65  $^{\circ}$ C for 1min, 65  $^{\circ}$ C to 55  $^{\circ}$ C ramping at  $-$   
66 0.3  $^{\circ}$ C /s, 55  $^{\circ}$ C for 1min, 55  $^{\circ}$ C to 45  $^{\circ}$ C ramping at  $-0.3$   $^{\circ}$ C/s, 45  $^{\circ}$ C for 1min,

67 45 °C to 35 °C ramping at -0.3 °C/s, 35 °C for 1min, 35 °C to 25 °C ramping  
68 at -0.3 °C/s, 25 °C for 1min. After heteroduplex formation, add 0.5ul T7  
69 Endonuclease I (NEB) and hold at 37 °C for 1 hour. The digested products  
70 were analyzed by 10% polyacrylamide gel run in 1×TBE. The indel rate  
71 was calculated with ImageJ software.

## 72 **FACS analysis and ESC clone derived from single cell**

73 ES cells were harvested 3 days post transfection by TrypLE Express  
74 digestion. The rate of GFP-positive cells was measured by MoFlo XDP  
75 flow cytometer and analyzed with Summit Software. Single GFP-positive  
76 cell was sorted into each well of the prepared 96-well plate.

## 77 **Immunofluorescence staining**

78 ES cells were fixed with freshly prepared 4%  
79 paraformaldehyde/PBS for 30min at room temperature with shaking, and  
80 permeabilized with PBS containing 0.2% Triton X-100 for 30min at room  
81 temperature. Next, to avoid non-specific reaction, the ES cells were  
82 blocked with PBS containing 5% serum for 1 hour at room temperature,  
83 cells were incubated overnight at 4 °C with primary antibodies against  
84 Tbx3 (sc-17871, Santa Cruz), Oct4 (sc-5729, Santa Cruz), Nanog  
85 (ab80892, Abcam), Sox2 (ab97959, Abcam). Nestin (ab6142, Abcam),  
86 SMA (ab5694-100, Abcam), Gata4 (sc-1237, Santa Cruz). After washed  
87 three times in PBS, the cells were incubated with Alexa Fluor 594 donkey  
88 anti-goat IgG (A-11058, Invitrogen), Alexa Fluor 594 Goat Anti-Mouse

89 IgG Antibody (A-11032, Invitrogen), Alexa Fluor 594 Goat Anti-Rabbit  
90 IgG Antibody (A-11037, Invitrogen), Alexa Fluor 488 Goat Anti-Mouse  
91 IgG Antibody (A-11001, Invitrogen) or Alexa Fluor 594 Donkey  
92 Anti-Goat IgG Antibody (A-11058, Invitrogen) for 1 hour at room  
93 temperature. At last the nucleus was labeled with DAPI. Fluorescent  
94 images were captured using a Nikon A1 Confocal Laser Microscope  
95 system.

### 96 **Embryonic Microinjection**

97 To guarantee the injection of ES cells into eight-cell stage embryo  
98 before compaction, we collected the two-cell stage embryo and cultured  
99 *in vitro*. For production of two-cell stage embryos, 6-week old females  
100 were superovulated with intraperitoneal injection of pregnant mare serum  
101 gonadotrophin (PMSG ) (10 IU/mouse, Ningbo Second Hormone Factory)  
102 48 hours before mating, and human chorionic gonadotrophin (hCG) (50  
103 IU/mouse, Ningbo Second Hormone Factory) 2 hours before mating. At  
104 the next morning, labeled the female with vaginal plugs (0.5 days post  
105 coitum, dpc). Two-cell stage embryos were flushed from oviduct of  
106 plugged females at 1.5dpc in M2 medium (Millipore), and cultured at  
107 37 °C/5% CO<sub>2</sub> in KSOM medium (Millipore) covered with mineral oil  
108 (Sigma). Microinjection was performed at the next day (2.5dpc). Zona  
109 pellucida (ZP) was perforated using micropipette with the help of Piezo  
110 (PMM-150FU Piezo, Sutter instrument). About fifteen ES cells were

111 introduced into perivitelline space through the perforation in the ZP.  
112 Injected embryos were cultured to develop into blastocyst *in vitro* as  
113 described above.

#### 114 **Embryo transfer**

115 We used CD1 females mated with vasectomized CD1 males as  
116 recipients for injected embryos. We usually prepared two kinds of  
117 recipients which were 2.5dpc and 0.5dpc, depending on the development  
118 stage of injected embryos. For blastocyst stage, twelve to fifteen embryos  
119 were transferred into uterus of 2.5dpc pseudopregnan CD1 females and  
120 morula stage embryos into oviduct of 0.5dpc recipients.

#### 121 **Southern blot analysis**

122 Genomic DNA of cells and tails of mice were extracted using the  
123 method of phenol-chloroform extraction. A total of 5 µg genomic DNA  
124 was separated on a 0.7% agarose gel after digested by BglII (NEB), and  
125 then transferred to a nylon membrane (Roche) and hybridized with PCR  
126 based Dig(Roche)-labeled probes.

#### 127 **Immunohistochemistry**

128 After fixation in 4% PFA, the embryo was dehydrated in a series of  
129 grade ethanol, embedded in paraffin and cut into section. Heat induced  
130 epitope retrieval was performed using citrate buffer (pH 6.0). For  
131 detection of GFP, we use anti-GFP rabbit monoclonal antibody (2956S,  
132 Cell Signaling) at 1:200 dilution rate.

### 133 **Real-time (quantitative) PCR**

134 Total RNA was extracted using RNeasy Mini Kit (Qiagen) in  
135 accordance with the manufacturer's protocol. cDNA were synthesized  
136 with oligo-dT primer by M-MLV Reverse Transcriptase Kit (Promega).  
137 Q-PCR reactions were performed using the SYBR Green I Master Mix  
138 and LightCycler 480 (Roche). Gene-specific primers for Q-PCR can be  
139 found at previous study (Han et al., 2010).

### 140 **Prediction and detection of potential off targets**

141 We screened potential off target sites around the mouse genome  
142 (mm10) with CasOT software (Xiao et al., 2014) based on the role:  
143 screened potential target sites allowing for up to three base pair  
144 mismatches compared with sgRNA and the other three different PAM in  
145 the first base pair (Hsu et al., 2013). Genomic DNA regions around  
146 potential off target sites were amplified, purified and analyzed by T7EN I  
147 analysis as described above.

### 148 **Statistical analyses**

149 Student's t-tests were used to compare differences between any two  
150 groups.

151

152 Table S1. Off-target Analysis, Related to Figure 1 and S3.

Site name	Coordinate	Sequence	Indel mutation frequency (Mutant/Total)
Tbx3	5:119683061-119683083:+	AGCCAGACAGGTCTTGCAGC-GGG	/
OT1	1:172492216-172492239:+	AG <u>a</u> C <u>g</u> GACAGG <u>c</u> CTTGCAGC- <u>t</u> GG	0/10
OT2	1:189903526-189903549:+	AG <u>a</u> CAGACAGGTCT <u>g</u> GCAG <u>g</u> -GGG	0/10
OT3	3:89081084-89081107:+	AGCCAGACAGG <u>a</u> CTT <u>c</u> CAG <u>t</u> -GGG	0/10
OT4	4:140147710-140147733:+	AGCCAGA <u>a</u> AGGTCT <u>g</u> GCAG <u>t</u> - <u>t</u> GG	0/10
OT5	5:114444949-114444972:+	AG <u>a</u> CAGACAGG <u>c</u> CTTGC <u>t</u> GC- <u>t</u> GG	0/10
OT6	8:54554792-54554815:-	AGCCAGACAG <u>t</u> <u>g</u> cTGCAGC- <u>a</u> GG	0/10
OT7	10:86070612-86070635:-	AGCC <u>a</u> ACAGGT <u>a</u> T <u>g</u> GCAGC- <u>t</u> GG	0/10
OT8	11:84710571-84710594:+	AGCCAGA <u>g</u> AGG <u>g</u> CTT <u>g</u> tAGC- <u>a</u> GG	0/10
OT9	12:110269346-110269369:+	AGCCAGACAGG <u>g</u> CTT <u>c</u> tGC- <u>a</u> GG	0/10
OT10	19:27716654-27716677:+	AGCC <u>a</u> ACAGG <u>g</u> CTTGCA <u>a</u> C- <u>a</u> GG	0/10
OT11	X:166592140-166592163:-	AG <u>a</u> CAGACA <u>a</u> <u>g</u> cCTTGCAGC-aGG	0/10

153 Mismatches between potential off-target site and on-target sequence are shown in lower-case, boldface  
 154 and underlined. Sequence of PAM and sgRNA is separated by hyphen. Coordinate shows the location of  
 155 potential off-target site in mice genome. Indel mutation frequencies in targeted mice were calculated by  
 156 T7EI assay. OT indicates off-target; /, not tested.

157

158 Table S2. Oligonucleotides used for constructing sgRNA expression vector

Gene target	Direction	Sequence (5'to 3')
<i>Tbx3</i>	F	CACCGAGCCAGACAGGTCTTGCAGC
	R	AAACGCTGCAAGACCTGTCTGGCTC
<i>GFP</i>	F	CACCGCGCGCCGAGGTGAAGTTCGA
	R	AAACTCGAACTTCACCTCGGCGCG

159

160 Table S3 Oligonucleotides used for T7EI assay and genotyping

Primer	Function	Sequence (5'to 3')
GF	Genotyping Internal probe	ATGGTGAGCAAGGGCGAG
GR		TTACTTGTACAGCTCGTCCATGCCGT
OF	Genotyping T7EI assay	TCCCCACTCTCTAACTCCCTATGT
OR		GTCTCTGGAAAGGCTTTAGTGCTC
Tbx3-ex-F	external probe	TGGAAGATACTAAGATACTGTGTGC
Tbx3-ex-R		TTGGGTGACAAGGACACTGA

161

162 Table S4 Oligonucleotides used for construction of Donor plasmid

Primer	Function	Sequence (5'to 3')
Tbx3-LA-F	Left homologous arm	ATGGCGCGCCTCAAGTGCCTCAGTATCCTG
Tbx3-LA-R		TTCCTCCACGTCACCGCATGTTAGAAGACTTCCTCTGCCCTCC GGTGAGCCACTGCAAGACCTGTCTGGCTTGG
T2A-GFP-F	2A-eGFP	GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGA ATCCCGGCCCTATGGTGAGCAAGGGCGAG
T2A-GFP-R		GGTACCTTACTTGTACAGCTCGTCCATGCCGT
Tbx3-RA-F	Right homologous arm	ATCGATAAACAAGAAAAACAAAATCGC
Tbx3-RA-R		GGTACCACAATTCAATAAATTAAGTT

163

164 Table S5 Oligonucleotides used for off-targeted analysis

Gene target	Direction	Sequence (5'to3')
OT1-Tbx3-Stop	F	TACCATATTGCAGCCGCTTAC
	R	CTTCTTCTCACCTCCACAGTCA
OT2-Tbx3-Stop	F	AAGTCTGGAACCTCGGCGTCTG
	R	GGGTGCTGGAACTGAACCTC
OT3-Tbx3-Stop	F	TGGTTGGTGGTCCATTGTTTG
	R	AGTTTCTGCTCCATCTTTATCC
OT4-Tbx3-Stop	F	GGAAGAGTGACAGGCATTGGT
	R	ACTCACGCCCTGCTGGGTTTA
OT5-Tbx3-Stop	F	TGGCAACAGCAGTGGTAATA
	R	GAGAAACAAAGTCCCTAGATG
OT6-Tbx3-Stop	F	TTGTGAGTCTACTGGGCTAT
	R	GTGCATTGTAACATGAGGC
OT7-Tbx3-Stop	F	AGTATCAGGACCCAAGCCAACC
	R	AGCAGCCACCCAGTAACACG
OT8-Tbx3-Stop	F	GATTCCAAGCACAGCCCTAA
	R	TGTGAAACTGGTCTCTCTG
OT9-Tbx3-Stop	F	GGCTTTGATAGAGGCAACTGG
	R	CTTGGGACTCGGGTCTTATGT
OT10-Tbx3-Stop	F	TGCTGGAGACAGACCACAAC
	R	CCAAACAGGGTGGCTACTTC
OT11-Tbx3-Stop	F	GCCTTTGTCTTGAGGGATGT
	R	AGTGTCCAGCACAGGATTAG

165

166

167 **Reference**

- 168 Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W.,  
169 Marraffini, L.A., *et al.* (2013). Multiplex genome engineering using CRISPR/Cas systems.  
170 Science 339, 819-823.
- 171 George, S.H., Gertsenstein, M., Vintersten, K., Korets-Smith, E., Murphy, J., Stevens, M.E.,  
172 Haigh, J.J., and Nagy, A. (2007). Developmental and adult phenotyping directly from mutant  
173 embryonic stem cells. Proc Natl Acad Sci U S A 104, 4455-4460.
- 174 Han, J., Yuan, P., Yang, H., Zhang, J., Soh, B.S., Li, P., Lim, S.L., Cao, S., Tay, J., Orlov, Y.L.,  
175 *et al.* (2010). Tbx3 improves the germ-line competency of induced pluripotent stem cells.  
176 Nature 463, 1096-1100.
- 177 Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine,  
178 E.J., Wu, X., Shalem, O., *et al.* (2013). DNA targeting specificity of RNA-guided Cas9  
179 nucleases. Nat Biotechnol 31, 827-832.
- 180 Xiao, A., Cheng, Z., Kong, L., Zhu, Z., Lin, S., Gao, G., and Zhang, B. (2014). CasOT: a  
181 genome-wide Cas9/gRNA off-target searching tool. Bioinformatics.

182

183 **Supplemental figure legends**

184 **Figure S1**

185 Generation of Tbx3-2A-GFP ESCs by using the CRISPR/Cas9  
186 system. (A) The homogeneous expression pattern of Tbx3 in the presence  
187 of 2i. Scale bars, 20  $\mu$ m. (B) Flow cytometry analysis and sorting of the  
188 GFP-positive cells after electrotransfection. (C) Immunofluorescence

189 staining of Tbx3-2A-GFP ESCs. Cells were stained with the pluripotency  
190 markers Oct4, Sox2 and Nanog. Scale bars, 20  $\mu$ m. (D) PCR screening of  
191 Tbx3-2A-GFP knock-in ESCs. OF, outside forward primer; OR, outside  
192 reverse primer; GF, internal forward primer; GR, internal reverse primer;  
193 M, molecular marker; WT, wild type. € Immunofluorescence staining of  
194 embryoid body (EB) formed from modified ESCs on day 7. Cells were  
195 stained for three germ layer markers Nestin (ectoderm),  $\alpha$ -SMA  
196 (mesoderm) and Gata4 (endoderm). Scale bars, 20  $\mu$ m.

### 197 **Figure S2**

198 Near 100% ESC-derived mice yielded by eight-cell stage embryo  
199 injection. (A) Blastocyst development from eight-cell stage embryo  
200 injected with Tbx3-2A-GFP ESCs. Scar bars, 100  $\mu$ m. (B) F0 generation  
201 of reporter knock-in mice were identified by southern blot analysis. T,  
202 targeted knock-in mice. (C) F1 offsprings of Tbx3-2A-GFP mice mating  
203 with wild-type CD-1 females. (D) Summary of F1 generation of  
204 Tbx3-2A-GFP mice mating with wild-type CD-1 females. (E) GFP  
205 fluorescein images of early embryos from F1 offsprings of reporter  
206 knock-in mice (related to Fig. S2D). Scar bars, 1mm.

### 207 **Figure S3**

208 Schematic overview of generating Tbx3-2A-GFP mice by  
209 CRISPR/Cas9 system and eight cell-stage embryo injection technology.  
210 Segments on the right side indicate time needed for each step; FACS,

211 Fluorescence-activated cell sorting.

212